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Concurrent analysis of antibiotic resistance of colonis-
ing and invasive Streptococcus pneumoniae gives a 
more accurate picture than looking at either of them 
separately. Therefore, we analysed 2,129 non-inva-
sive and 10,996 invasive pneumococcal isolates from 
Switzerland from 2004 to 2014, which spans the time 
before and after the introduction of the heptavalent 
(PCV7) and 13-valent (PCV13) conjugated pneumo-
coccal polysaccharide vaccines. Serotype/serogroup 
information was linked with all antibiotic resistance 
profiles. During the study period, the proportion of 
non-susceptible non-invasive and invasive isolates sig-
nificantly decreased for penicillin, ceftriaxone, erythro-
mycin and trimethoprim/sulfamethoxazole (TMP-SMX). 
This was most apparent in non-invasive isolates 
from study subjects younger than five years (penicil-
lin (p = 0.006), erythromycin (p = 0.01) and TMP-SMX 
(p = 0.002)). Resistant serotypes/serogroups included 
in PCV7 and/or PCV13 decreased and were replaced by 
non-PCV13 serotypes (6C and 15B/C). Serotype/sero-
group-specific antibiotic resistance rates were com-
parable between invasive and non-invasive isolates. 
Adjusted odds ratios of serotype/serogroup-specific 
penicillin resistance were significantly higher in the 
west of Switzerland for serotype 6B (1.8; 95% confi-
dence interval (CI): 1.4–4.8), 9V (3.4; 95% CI: 2.0–5.7), 
14 (5.3; 95% CI: 3.8–7.5), 19A (2.2; 95% CI: 1.6–3.1) and 
19F (3.1; 95% CI: 2.1–4.6), probably due to variations in 
the antibiotic consumption.
Introduction
Antibiotic resistance in Streptococcus pneumoniae is a 
worldwide concern and can lead to treatment failures 
with increase in morbidity and mortality, augmented 
treatment cost and use of more toxic reserve antimi-
crobials [1,2]. In this context, surveillance of antibiotic 
resistance in S. pneumoniae is important for the appro-
priate choice of empirical therapy, to detect new resist-
ance developments in a timely manner and to monitor 
the effect of interventions such as antibiotic steward-
ship campaigns or vaccines on resistance rates and 
serotype distribution [3].
Heptavalent conjugated pneumococcal polysaccharide 
vaccine (PCV7) followed by 13-valent vaccine (PCV13) 
have been recommended and reimbursed by the health 
insurance in Switzerland since late 2006 and 2011, 
respectively, for all children younger than two years 
[4]. During the period from 2008 to 2010, the pneu-
mococcal vaccine coverage was, respectively, ca 50% 
(95% confidence interval (CI): 46.0–53.5) and 37% 
(95% CI: 32.5–41.6) for two and three doses at the age 
of two years [4]. The coverage increased to 79% (95% 
CI: 77.4–80.4) and 75% (95% CI: 73.8–76.7), respec-
tively, for two and three doses between 2011 and 2013. 
Introduction of vaccines led to a decrease in the inci-
dence in invasive pneumococcal disease (IPD) but also 
to a change in serotype redistribution across all ages 
[4]. In other countries, vaccine introduction has addi-
tionally led to a decrease in antibiotic resistance rates 
because the less susceptible serotypes have been 
included in the vaccines [5]. So far, in Switzerland, 
antibiotic resistance in S. pneumoniae has only been 
analysed in the pre-PCV7 era from 2001 to 2004 [6].
Ideally, antibiotic resistance rates in non-invasive 
and invasive S. pneumoniae are analysed simultane-
ously, but such studies of representative size are rare 
or often not very recent [6,7] because in many coun-
tries, antibiotic resistance data is exclusively drawn 
from surveillance of invasive isolates. Switzerland runs 
two different national surveillance systems collecting 
resistance data on S. pneumoniae: sentinel surveillance 
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Figure 1
Proportions of non-susceptibility of Streptococcus pneumoniae isolates, Switzerland, 2004–14 (n = 13,125)
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IPD: invasive pneumococcal disease; TMP-SMX: trimethoprim/sulfamethoxazole.
Antibiotic resistance towards penicillin includes isolates with MIC > 0.06 mg/L
Samples for which age group was not known (n = 681) are excluded from this analysis.
Analyses were stratified according to IPD in patients < 5 years (A), 5–64 years (B), > 64 years of age (C) and non-IPD in patients < 5 years of age 
(D). Data on non-IPD in patients 5–64 years and > 64 years of age were omitted due to low number of isolates in these two categories.
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of outpatient non-invasive pneumococci (Sentinella) 
and comprehensive passive surveillance of all invasive 
pneumococci [4,8]. The aims of this study were (i) to 
simultaneously describe the prevalence of antibiotic 
resistance in invasive and non-invasive S. pneumo-
niae in different patient populations in Switzerland 
from 2004 to 2014, (ii) to analyse possible temporal 
trends and effects of PCV7 and PCV13 on resistance 
prevalence, (iii) to detect serotype/serogroup-specific 
antibiotic resistance and (iv) to analyse regional differ-
ences for the antibiotic resistance rates.
Methods
Sentinel surveillance of non-invasive 
pneumococcal isolates (Sentinella)
Between 2004 and 2014, data on colonising pneumo-
cocci were obtained from a nationwide, ongoing, pro-
spective surveillance study within the Swiss Sentinel 
System which has been described in detail previously 
[8]. In brief, this network involves a chosen sample of 
practitioners who represent Switzerland geographi-
cally and demographically. The overall number of par-
ticipants per subspecialty in the Sentinel System is 
defined as a proportion of all Swiss practitioners in 
the matching specialty [8,9]. Therefore, ca 200 practi-
tioners (general practitioners, internists and paediatri-
cians) took samples of outpatients who were clinically 
diagnosed with acute otitis media or pneumonia [8]. 
All received swabs were cultured for S. pneumoniae at 
the Swiss National Reference Centre for Pneumococci 
(NZPn) as described [6].
Comprehensive surveillance of invasive 
pneumococcal isolates
Physician reporting of invasive pneumococcal infection 
has been mandatory in Switzerland since 1999 (http://
www.bag.admin.ch). In March 2002, the NZPn was set 
up and has since been prospectively collecting clinical 
pneumococcal isolates from normally sterile body sites 
(blood, cerebrospinal, joint, pleural and peritoneal 
fluid but not middle ear fluid) sent in by Swiss clinical 
microbiology laboratories. It is possible to link ca 90% 
of physician-reported IPD cases with a corresponding 
pneumococcal isolate, indicating a very high partici-
pation of involved laboratories and a high complete-
ness of data linkage [4]. This study uses only the NPZn 
isolates and demographic data associated with them. 
Physician-reported data are not included in the analy-
sis in this study.
Analysis of non-invasive and invasive isolates
All isolates were confirmed as S. pneumoniae by alpha 
haemolysis morphology on blood agar plates, bile sol-
ubility and optochin sensitivity. Serotypes of all con-
firmed pneumococcal isolates were determined by the 
Quellung reaction.
Methods for antibiotic resistance testing were identi-
cal for non-invasive and invasive isolates and have 
been described previously [8]. In brief, all isolates 
were tested against oxacillin (1 μg disk), erythromycin, 
trimethoprim/sulfamethoxazole (TMP-SMX) and levo-
floxacin by the disk diffusion method. For isolates with 
reduced susceptibility to oxacillin, the minimum inhibi-
tory concentration (MIC) against penicillin and ceftri-
axone was determined by Etest (AB Biodisk) according 
to Clinical and Laboratory Standards Institute (CLSI) 
[10]. During the study period, CLSI introduced new MIC 
breakpoints for parenteral penicillin therapy of non-
meningitis infections. To ensure that the same break-
points were applied for all isolates over the entire 
study period, we used the oral non-meningitis break-
points (susceptible (S) ≤ 0.06 mg/L or oxacillin disk 
diameter ≥ 20 mm) for penicillin non-susceptibility and 
the meningitis (S ≤ 0.5 mg/L) breakpoints for ceftriax-
one non-susceptibility for the entire time period.
For this study, data for isolates collected between 
January 2004 and December 2014 were analysed. Data 
on patients’ age, sex and geographical origin of sam-
ples were available for all isolates except 681 records 
with missing data on age and 6 records with missing 
data on geographical region. 
Statistical analysis
Resistance prevalence data were stratified by age 
group (< 5, 5–64 and > 64 years), serotype/serogroup 
and geographical region. For geographical compari-
sons, Switzerland was divided into two regions, the 
French speaking western part designated ‘west’ 
and the remaining parts of the country including the 
Italian speaking canton Ticino designated ‘other’, as 
described previously [6]. Differences were calculated 
using 2 × 2 or 3 × 2 chi-square test. Changes over time 
from 2004 to 2014 were analysed with the chi-square 
test for trend with CDC EpiInfo Version 7 and GraphPad 
Prism version 6.00 for Windows, GraphPad Software. A 
cut-off value of p ≤ 0.05 (two-tailed) was used for these 
tests.
Serotype/serogroup-specific antibiotic non-suscep-
tibilities of pencillin, erythormycin or TMP-SMX of 
invasive and colonising S. pneumoniae isolates were 
calculated by multivariate logistic regression analysis. 
Adjusted odds ratios (aOR) with 95% confidence inter-
vals (95% CI) were received for serotypes/serogroups 
with overall proportions of above 1%. For all six regres-
sion analyses, the remaining serotypes, consisting of 
serotypes/serogroups with overall proportions below 
1% in invasive and non-invasive S. pneumoniae, served 
as the reference group.
Serotype/serogroup-specific antibiotic resistance by 
geographical region and isolation site (i.e. colonising 
vs invasive S. pneumoniae) for the top four resistant 
serotypes for penicillin, erythromycin and trimetho-
prim/sulfamethoxazole (TMP-SMX) was also calculated 
by multivariate logistic regression analysis. Isolates 
from the ‘other’ part of Switzerland were used as the 
reference group for each of the 12 regression analyses. 
4 www.eurosurveillance.org
Figure 2
Serotype/serogroup-specific multivariate logistic regression analysis, Streptococcus pneumoniae isolates, Switzerland, 
2004–14 (n = 12,438)
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Logistic regression analyses were performed using 
Stata (version 13.0).
Results
In total, 2,129 non-invasive and 10,996 invasive pneu-
mococcal isolates from January 2004 to December 
2014 were analysed (Table 1). The patient population 
with non-invasive S. pneumoniae had a significantly 
higher proportion of children younger than five years 
than the patient population with invasive isolates 
(Table 1; p < 0.001). This is because non-invasive iso-
lates were received from patients with pneumonia 
(n = 285), but more often from patients with acute otitis 
media (n = 1,775) who are mostly toddlers. For 69 iso-
lates, the underlying disease was unknown. In general, 
isolates from the west were overrepresented among 
the non-invasive isolates and proportional to the resi-
dent population among the invasive isolates (Table 1).
Overall, we identified 22 serotypes/serogroups with a 
prevalence of more than 1.0% (serotypes/serogroups 1, 
3, 4, 6A, 6B, 6C, 7F, 8, 9, 9V, 10, 11, 14, 15, 18C, 19A, 
19F, 22F, 23, 23F, 33 and 35). The proportions of iso-
lates with PCV7 serotypes did not differ between the 
non-invasive and the invasive isolates in any of the 
three chosen age categories (< 5 years, 5–64 years 
and > 64 years). In contrast, differences were noted for 
the PCV13 minus PCV7 (serotypes/serogroups 1, 3, 
5, 6A, 7F, 19A) and non-PCV13 serotypes/serogroups 
Table 1
Characteristics of invasive (n = 10,996) and non-invasive (n = 2,129) pneumococcal isolates, Switzerland, 2004–14
Non-invasive Streptococcus pneumoniae Invasive Streptococcus pneumoniae
n % n % pa 
Total isolates 2,129 100.0 10,996 100.0 NA
Age 
< 5 years 1,347 63.3 657 6.0 <0.001
5–64 years 710 33.3 4,164 37.9 <0.001 
> 64 years 70 3.3 5,496 50.0 <0.001
Not known 2 0.1 679 6.2 <0.001
Region 
West 856 40.2 2,781 25.3 <0.001
Other 1,271 59.7 8,211 74.7 <0.001
Not known 2 0.1 4 0.0 0.3
Non-susceptibility 
Penicillinb 299 14.0 1,077 9.8 <0.0001
Ceftriaxone 35 1.6 242 2.2 0.04
Erythromycin 256 12.0 1,295 11.8 0.7
TMP-SMX 328 15.4 1,540 14.0 0.09
Levofloxacin 1 0.0 41 0.4 0.02
Serotype/serogroup c 
Age < 5 years n = 1,347 n = 657 
PCV7 532 39.5 242 36.8 0.3
PCV13 minus PCV7 379 28.1 280 42.6 <0.0001
Non-PCV13 436 32.4 135 20.4 <0.0001
Age 5–64 years n = 710 n = 4,164 
PCV7 212 29.9 1,228 29.5 0.8
PCV13 minus PCV7 283 39.9 1,667 40.0 0.9
Non-PCV13 215 30.3 1,269 30.5 0.9
Age > 64 years n = 70 n = 5,495 
PCV7 17 24.3 1,816 33.0 0.1
PCV13 minus PCV7 18 25.7 1,911 34.8 0.1
Non-PCV13 35 50.0 1,768 31.2 0.002
NA: not applicable; TMP-SMX: trimethoprim/sulfamethoxazole.
a p value calculated with 2 × 2 chi-square test. 
b Minimal inhibitor concentration > 0.06 mg/L.
c PCV7: serotypes/serogroups 4, 6B, 9V, 14, 18C, 19F, 23F; PCV13 minus PCV7: serotypes/serogroups 1, 3, 5, 6A, 7F, 19A; PCV13: serotypes/
serogroups 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, 19A; Non-PCV13: all remaining serotypes/serogroups. For two and 679 non-invasive 
and invasive isolates, respectively, age was unknown. For one invasive isolate, the serotype/serogroup was unknown.
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within individuals younger than five years and older 
than 64 years (Table 1). 
Antibiotic resistance rates were highest in children 
younger than five years, for both invasive and non-
invasive isolates, for all tested antibiotics (penicil-
lin, ceftriaxone, erythromycin and TMP-SMX) with 
the exception of levofloxacin (Table 2). In general, 
antibiotic resistance rates were comparable between 
invasive and non-invasive isolates in all age groups. 
Non-susceptibility was higher in western Switzerland 
for penicillin, ceftriaxone, erythromycin and TMP-SMX 
for invasive as well as non-invasive isolates (Table 2).
Time trends of pneumococcal antibiotic 
resistance prevalence
We subsequently analysed the temporal evolution of 
antibiotic non-susceptibility rates for three different 
age groups (Table 3 and Figure 1). Chi-square test for 
trend over the individual years 2004 to 2014 showed 
significant decreasing trends for penicillin, erythromy-
cin and TMP-SMX non-susceptibility in patients five to 
64 years of age with invasive isolates. The same was 
true for the same three antibiotics in children younger 
than five years with non-invasive pneumococci. Further 
significant downward trends of non-susceptibility were 
seen in invasive isolates for erythromycin in the under 
five-year-olds and for ceftriaxone and TMP-SMX in the 
elderly (> 64 years). The lowest non-susceptibility rates 
overall were found in the most recent years (2013–14), 
representing three and eight years, respectively, after 
the PCV13 and PCV7 vaccination recommendations for 
children under the age of two years.
Serotype/serogroup-specific antibiotic 
resistance was independent of the site of 
isolation
Figure 2 shows serotype/serogroup-specific antibiotic 
resistance for the three antibiotics penicillin, erythro-
mycin and TMP-SMX. Results for ceftriaxone and levo-
floxacin were omitted as the numbers were low. The 
aORs were calculated for 22 serotypes/serogroups with 
individual proportions of above 1% overall (non-inva-
sive and invasive isolates pooled). The serotypes con-
sisting of serotypes/serogroups with overall individual 
proportions below 1% served as the reference group.
Overall, ranking order of aORs of being non-susceptible 
revealed remarkable similarities between non-invasive 
Table 2
Antibiotic-resistant pneumococcal isolates by age and geographical origin of samples, Switzerland, 2004–14 (n = 13,125)
<5 years 5–64 years >64 years
Pa 
Westb Otherc
Pd 
n % n % n % n % n %
Resistance Invasive
Penicillin 
(MIC > 0.06 mg/L) 114 17.4 392 9.4 483 8.8 <0.0001 449 16.1 628 7.6 <0.0001
Penicillin 
(MIC > 2.0 mg/L) 10 1.5 32 0.8 28 0.5 0.008 30 1.1 45 0.5 0.003
Ceftriaxonee 33 5.0 86 2.1 98 1.8 <0.0001 121 4.4 121 1.5 <0.0001
Erythromycine 125 19.0 440 10.6 646 11.8 <0.0001 425 15.3 870 10.6 <0.0001
TMP-SMXe 124 18.9 601 14.4 693 12.6 <0.0001 479 17.2 1059 12.9 <0.0001
Levofloxacine 1 0.2 8 0.2 29 0.5 0.02 10 0.4 31 0.4 0.9
Totalf 657 100.0 4,164 100.0 5,496 100.0 NA 2,781 100.0 8,211 100.0 NA 
Resistance non-invasive
Penicillin 
(MIC > 0.06 mg/L) 226 16.8 70 9.9 3 4.3 <0.0001 175 20.4 124 9.8 <0.0001
Penicillin 
(MIC > 2.0 mg/L) 9 0.7 3 0.4 1 1.4 0.5 9 1.1 4 0.3 0.03
Ceftriaxonee 25 1.9 9 1.3 1 1.4 0.6 25 2.9 10 0.8 <0.0001
Erythromycine 205 15.2 4 6.6 4 5.7 <0.0001 151 17.6 105 8.3 <0.0001
TMP-SMXe 227 16.9 92 13.0 9 12.9 0.06 150 17.5 178 14.0 0.03
Levofloxacine 0 0 1 0.1 0 0 0.4 0 0 1 0.1 0.4
Totalf 1,347 100.0 710 100.0 70 100.0 NA 856 100.0 1,271 100.0 NA 
MIC: minimum inhibitory concentration; NA: not applicable.
Samples for which age group (n = 681) and/or geographical origin (n = 6) were not known are excluded from the respective analyses.
a p value calculated with 3 × 2 chi-square test.
b Includes the French-speaking and bilingual French- and German-speaking Swiss Cantons.
c Includes the German- and Italian-speaking Cantons.
d p value calculated with 2 × 2 chi-square test.
e Includes isolates with intermediate (i) and full antibiotic resistance (r).
f Total number of isolates tested for antibiotic resistance. Susceptible isolates are not shown, but included in the total. 
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and invasive S. pneumoinae isolates. The four sero-
types with lowest susceptibility and therefore with the 
highest aORs for penicillin were identical in the groups 
of non-invasive and invasive isolates (19A, 19F, 14 and 
15; Figures 2A and B). For TMP-SMX, the order of aORs 
was different between invasive and non-invasive iso-
lates, but the serotype with the lowest susceptibility 
(serotype 9V) was again identical (Figures 2C and D). 
Finally, serogroups 14 and 33 had the highest aORs 
for erythromycin non-susceptibility in both collections 
(Figures 2E and F). Thus, a distinct, serotype-specific 
antibiotic resistance exists and is likely to be independ-
ent of the anatomical isolation site (Figures 2A-2F).
Most serotypes revealing significantly higher antibiotic 
resistance rates than the reference group were covered 
by PCV13 (Figures 2A-2F), and indeed, introduction of 
the vaccine mitigated the prevalence of pneumococ-
cal antibiotic resistance (Table 3). However, non-PCV13 
serogroups/serotypes 15, 6C and 33 were also associ-
ated with increased antibiotic resistance to penicillin 
and/or erythromycin.
Serotype/serogroup distribution by 
geographical region
We calculated the serotype/serogroup-specific anti-
biotic resistance of the four most resistant S. pneu-
moniae serotypes for the three antibiotics penicillin, 
TMP-SMX and erythromycin by geographical region in 
Switzerland (west vs other; Table 4). We found that the 
geographical region had a profound effect on sero-
type/serogroup-specific antibiotic resistance (Table 
4). In order to determine if these differences were sig-
nificant, we performed a logistic regression for each 
Table 3
Time trends of non-susceptibility of pneumococcal isolates by yeara, Switzerland, 2004–14 (n = 13,125)
Age 
(years) Non-susceptibility 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total Trend
b
Invasive S. pneumoniae
< 5 
Penicillin 11 14 12 17 12 11 12 8 9 1 7 114 1
Ceftriaxone 2 7 3 6 4 4 2 1 3 0 1 33 0.2
Erythromycin 18 23 11 15 20 6 9 11 5 3 4 125 0.008 
TMP-SMX 20 14 16 12 15 13 9 7 8 3 7 124 0.2
5–64 
Penicillin 43 48 28 31 42 46 45 28 37 25 19 392 0.009 
Ceftriaxone 5 15 2 16 7 11 12 4 5 7 2 86 0.08
Erythromycin 46 39 41 49 46 66 40 29 37 29 18 440 0.0005 
TMP-SMX 82 76 39 63 72 53 46 39 40 52 39 601 <0.0001 
> 64 
Penicillin 29 43 48 48 45 47 68 47 46 34 28 483 0.4
Ceftriaxone 3 13 9 20 7 13 15 4 8 5 1 98 0.01 
Erythromycin 44 50 65 84 76 61 53 56 57 51 49 646 0.1
TMP-SMX 80 88 53 69 68 68 64 48 68 44 43 693 <0.0001 
Totalc 855 943 874 998 1,076 1,082 950 974 852 926 787 NA 
Non-invasive S. pneumoniae
< 5
Penicillin 44 46 44 24 15 13 18 16 6 3 1 230 0.006 
Ceftriaxone 3 4 3 5 3 4 3 0 0 0 0 25 0.6
Erythromycin 38 43 38 24 12 10 13 13 8 3 3 205 0.01 
TMP-SMX 52 50 33 24 14 7 15 14 6 7 5 227 0.002 
5–64
Penicillin 14 9 10 8 5 10 4 1 3 5 1 70 0.4
Ceftriaxone 2 0 2 2 2 1 0 0 0 0 0 9 0.3
Erythromycin 7 7 6 4 2 7 5 0 5 4 0 47 0.6
TMP-SMX 8 26 14 7 10 7 5 3 6 2 4 92 0.4
> 64
Penicillin 1 0 1 1 0 0 0 0 0 0 0 3 0.08
Ceftriaxone 0 0 1 0 0 0 0 0 0 0 0 1 0.4
Erythromycin 0 0 1 0 1 0 0 1 1 0 0 4 0.8
TMP-SMX 2 1 1 1 1 1 0 0 1 0 1 9 0.2
Totalc 340 344 354 193 181 182 137 147 118 70 61 NA 
NA: not applicable; TMP-SMX: trimethoprim/sulfamethoxazole.
Samples for which age group was not known (n = 681) are excluded from this analysis.
a White shading: pre-PCV7 years; light grey shading: post-PCV7 but pre-PCV13 years; dark grey shading: post-PCV13 years.
b p value calculated by chi-square test for trend. Significant p values indicated in bold (i.e. p < 0.05).
c Total number of isolates tested in all three age groups combined for which patient age was known (total invasive isolates: n = 10,317; total 
non-invasive isolates: n = 2,127). Susceptible isolates are not shown, but included in the total. 
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serotype/serogroup, using the isolates from the other 
part of Switzerland as the reference group.
For penicillin, erythromycin and TMP-SMX, three of four 
(14, 19F and 19A), four of four (33, 15, 19A and 14) and 
two of four serotypes/serogroups (9V, 23F) showed 
significantly higher rates in the west than in the rest 
of the country. This may partly explain the higher non-
susceptibility rates for all antibiotics found in the west 
compared with the rest of the country (Table 2).
Discussion
Our study concurrently compared antibiotic resistance 
rates from the non-invasive and invasive pneumococcal 
surveillance systems in Switzerland from 2004 to 2014. 
Overall, serotype/serogroup and antibiotic resistance 
data was available for more than 13,000 non-invasive or 
invasive isolates. The main findings of this study were 
(i) that antibiotic resistance of pneumococci decreased 
after the vaccination recommendation of PCV7 and 
PCV13 and (ii) that patient age and geographical origin 
of samples had a greater influence on the epidemiol-
ogy of antibiotic resistance of pneumococci than the 
site of isolation (i.e. invasive or non-invasive).
Compared with other European countries, the antibiotic 
resistance rates of the isolates were generally lower 
in our setting [11]. The French pneumococcal surveil-
lance network analysed the antibiotic susceptibility of 
6,683 S. pneumoniae isolated from children with acute 
otitis media from 2001 to 2011 [12]. Non-susceptibility 
(intermediate and full resistance) rates in 2011 were 
57.3% for penicillin in these French isolates. It is gener-
ally difficult to compare absolute penicillin resistance 
data from different studies from different countries 
because the guidelines for the interpretation of antibi-
otic resistance have changed (e.g. to apply CLSI versus 
European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) breakpoints) However, we identified 
lower penicillin non-susceptibility rates of 14% within 
our non-invasive isolates in our study compared with 
the French study. One possible explanation for these 
discrepancies between two neighbouring countries 
might be outpatient antibiotic use which is very low in 
Switzerland compared with other European countries 
such as France [13].
Furthermore, we revealed that antibiotic resistance 
decreased over time in patients up to age 64 years from 
2004 to 2014. This can be attributed to the decrease 
of non-susceptible serotypes such as 19A, 9V, 6B, 23F 
and 14 among invasive and non-invasive S. pneumo-
niae, which is most likely due to PCV7 and PCV13 vac-
cination as seen in other studies [12,14-18]. However, 
it has to be noted that in patients older than 64 years 
with invasive S. pneumoniae, with the exception of 
TMP-SMX and ceftriaxone, resistance rates remained 
unchanged from 2004 to 2014, although a serotype 
redistribution took place also in this age group [4,19]. 
In the future, serotypes 6C and serogroups 15 and 35 
should be followed up carefully as they are the most 
prominent non-PCV13 serotypes associated with anti-
biotic resistance. Serotype 6C and serogroup 15 have 
been implicated in other recent studies as emerging, 
resistant serotypes [20,21].
Whether invasive and non-invasive pneumococcal iso-
lates inherently differ in resistance rates is still unclear 
[22,23]. In our study, differences in the ranking of ORs 
for penicillin, TMP-SMX and erythromycin between 
Table 4
Serotype/serogroup-specific penicillin resistance of invasive and colonising Streptococcus pneumoniae isolates, by 
geographical region, Switzerland, 2004–14 (n = 13,125)
Serotype/ 
serogoup Number of isolates
b Antibiotic
% SSR
Adjusted OR (95% CI) for Westa
All West Other
19A 884
Penicillin
32.4 44.9 25.9 2.2 (1.6–3.1)
19F 663 30.3 46.5 22.7 3.0 (2.0–4.4)
14 1,095 24.7 50.8 16.2 5.3 (3.8–7.4)
15 338 23.7 26.9 21.9 1.6 (0.9–2.9)
9V 526
TMP-SMX
44.9 58.0 40.2 2.1 (1.4–3.3)
23F 632 29.1 34.8 26.8 1.6 (1.1–2.5)
6B 374 27.8 28.6 27.5 1.0 (0.6–1.8)
18C 304 27.6 30.1 26.7 1.2 (0.6–2.2)
14 1,095
Erythromycin
49.3 61.9 45.2 1.8 (1.4–2.5)
33 160 33.1 54.4 24.6 3.7 (1.5–9.5)
19A 884 24.9 33.2 20.6 2.0 (1.4–2.8)
15 338 24.0 31.9 19.6 2.4 (1.4–4.3)
CI: confidence interval; OR: odds ratio; SSR: serotype-specific resistance; TMP-SMX: trimethoprim/sulfamethoxazole. 
a ORs of antibiotic-resistant serotypes were adjusted for year of isolation, age category and site of isolation (invasive versus non-invasive). 
Isolates from the ‘other’ part of Switzerland were used as the reference group. 
b Isolates with unknown age (n = 681) and/or geographical region known (n = 6) were excluded. Only results for serotypes/serogroups with 
high SSR are shown (i.e. 19A, 19F, 14, 15, 9V, 23F, 6B, 18C and 33).
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non-invasive and invasive S. pneumoniae were mini-
mal, after correcting for age, time and geographical 
region. Indeed, the rankings of the ORs of the more 
resistant serotypes for each of the three antibiotics 
were identical for invasive and non-invasive S. pneu-
moniae. However, the specific setting in which non-
invasive isolates were received may be crucial. While 
we used isolates collected in primary care in situa-
tions that do not normally warrant a microbiological 
diagnosis (uncomplicated otitis media and community-
acquired pneumonia), many other studies used data 
from non-invasive pneumococci generated in routine 
microbiological work-up [7,24,25]. It is well known that 
using routine microbiological data may select for more 
complicated and more often pre-treated cases, which 
in turn increases the chance of finding antibiotic-resist-
ant isolates [26,27]. We therefore think that the design 
of our network may reflect a more general situation of 
antibiotic resistance for these isolates.
Besides temporal trends, we also analysed geographi-
cal differences in resistance rates. We found that resist-
ance rates were higher in the west than in the rest of 
Switzerland. We saw only minor dissimilarities in over-
all serotype distribution, which cannot explain these 
geographical differences (data not shown). Therefore, 
an explanation for these discrepancies could be vary-
ing antibiotic consumption. Indeed, higher overall 
antibiotic consumption has been observed in western 
Switzerland in in- [28] and outpatients [13,29]. More 
specifically, a higher antibiotic consumption in the 
west was found for beta-lactams and macrolides but 
not for TMP-SMX. This is in line with the higher sero-
type/serogroup-specific resistance against penicillin 
and erythromycin but not against TMP-SMX that we 
observed in western Switzerland. A clear correlation 
between antibiotic resistance and outpatient use of 
penicillin has been described previously [11].
This study has some major strengths. It includes a 
large data volume, allowing for demographic and tem-
poral stratification and the parallel analysis of data 
from invasive and non-invasive isolates with a great 
statistical power. Furthermore, it includes congruent 
analysis of invasive and non-invasive samples in the 
same laboratory with the same methodology and con-
stantly over a long observation time of 11 years, span-
ning the introduction of PCV7 and PCV13 vaccines. The 
non-invasive samples were true outpatient samples 
and were collected by ca 200 practitioners, representa-
tive of Swiss primary care physicians.
There are some limitations to this study. Due to the 
characteristics of the collection of S. pneumoniae iso-
lates, patients with invasive S. pneumoniae differed 
significantly in age and regional origin from those with 
colonising S. pneumoniae. However, the large number 
of included isolates still allowed for subgroup analy-
sis and adjusting for potential confounding factors 
in logistic regression models. In addition, colonis-
ing S. pneumoniae were collected from patients with 
pneumococcal disease (acute otitis media or pneumo-
nia) but not from those with other diseases such as 
acute exacerbation of chronic obstructive pulmonary 
disease (AECOPD) [5,16] or from healthy people. Not 
including patients with AECOPD may reduce observed 
rates of antibiotic non-susceptibility as these patients 
are more likely to have received antibiotics (as dis-
cussed above) [26].
Conclusion
In summary, this is a detailed and comprehensive study 
analysing antibiotic resistance rates and serotype dis-
tribution with high statistical power in invasive and non-
invasive S. pneumoniae in Switzerland. We revealed 
that antibiotic non-susceptibility was highest in chil-
dren under five years of age. Furthermore, we showed 
that variations in the regional antibiotic consumption 
and the introduction of vaccines may have influenced 
antibiotic non-susceptibility rates. The introduction 
of PCV7 and PCV13 markedly reduced resistance rates 
in pneumococci in Switzerland, mainly by decreasing 
the prevalence of the most resistant serotypes/sero-
groups. Site of isolation (invasive vs non-invasive) by 
itself had a much more limited influence on the epide-
miology. At the end of the study period in 2014, dis-
tinct antibiotic resistance rates were on an all-time low 
for various age groups, but certain non-PCV13 resistant 
serotypes have to be carefully monitored in the future. 
The two described national surveillance systems are 
both important to guide future antibiotic stewardship 
and vaccination policies in Switzerland.
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